We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 177

Generics v Lundbeck - distinguishing the sufficiency requirements for product and process claims
  • Gowling WLG
  • United Kingdom
  • May 19 2008

In Generics v Lundbeck, the Court of Appeal provided important guidance on the judgment of the House of Lords in Biogen v Medeva regarding the scope of protection to which an inventor is entitled and the enabling disclosure the specification must provide to support the claims in the patent


PMPRB decisions and cases the year 2009 in review
  • Gowling WLG
  • Canada
  • February 3 2010

During 2009, a number of key decisions issued from panels of the Patented Medicine Prices Review Board (PMPRB) and the courts on issues relating to Canada's federal system of price control


Patent misuse in the pharmaceutical industry: developments in US & EU
  • Gowling WLG
  • European Union, USA
  • October 31 2007

The pharmaceutical industry has been scrutinised closely by competition authorities and courts in the US and Europe


'Round up' on the scope of DNA patents - Monsanto Technology LLC v Cefetra BV and others
  • Gowling WLG
  • Netherlands, European Union
  • March 17 2010

Since their inception, DNA sequence patents have proved a hot topic in patent law


Conflicting pharmaceutical trade marks
  • Gowling WLG
  • European Union
  • November 12 2008

The Court of First Instance (CFI) has upheld the opposition by Aventis Pharma SA (Aventis) against Nycomed GmbH's (Nycomed) application for the Community trade mark PRAZOL


Patent validity - the Lords take a step in the right direction
  • Gowling WLG
  • United Kingdom
  • July 10 2008

The House of Lords has delivered a patent law decision which is likely to be welcomed by innovative companies throughout the UK and the pharmaceutical industry in particular


Implemention of “Bolar” in the EU
  • Gowling WLG
  • European Union, United Kingdom
  • October 31 2007

In Europe, Directive 200427EC (amending Directive 200183EC) introduced into European Union legislation for the first time an exemption from patent infringement for conducting certain developmental work pre-patent expiry (the EU ‘Bolar’ exemption


Merck triumphs as new and inventive dosing regimen held patentable
  • Gowling WLG
  • United Kingdom
  • May 29 2008

Actavis sued to revoke Merck's patent with a second medical use claim (in the so-called 'Swiss form') for the use of finasteride in the preparation for a drug to treat androgenic alopecia with a lower dosage than disclosed in the prior art


Eli Lilly v. Apotex
  • Gowling WLG
  • Canada
  • May 4 2009

In the underlying decision on the merits, the Federal Court dismissed the application on the basis that the allegation as to a lack of sound prediction because the patent lacks adequate disclosure was justified


Lessons on chemical classes
  • Gowling WLG
  • United Kingdom
  • November 12 2008

In July this year, Wragge & Co's Intellectual Property team reported on the German Appeal Court decision on Eli Lilly's patent for the anti-psychotic drug olanzapine